Molecular Therapy — Methods & Clinical Development · 2018 · 240 citations · 10 references
Life SciencesBiotechnologyImmunologyAdaptive ImmunityClinical ImmunologyGenome EditingCrispr-cas SystemsDelivery Systems For Genome EditingTherapeutic Genome EditingCrispr-cas Genome EditingCrispr-cas TherapeuticsCrispr-cas9 Ex Vivo EditingCrispr-cas9 Genome EditingEx Vivo DeliveryEx Vivo Genome EditingIn Vivo Genome EditingPre-existing Immunity
(SpCas9) in human sera. Furthermore, using these assays to screen for pre-existing antibodies in 200 human serum samples, we found the prevalence of anti-SaCas9 and anti-SpCas9 antibodies to be 10% and 2.5%, respectively.
10
In vivo genome editing using Staphylococcus aureus Cas9
F. Ann Ran, Le Cong, Winston X. Yan et al. · Nature · 2015 · 2.7K citations · Full text
A multifunctional AAV–CRISPR–Cas9 and its host response
Wei Leong Chew, Mohammadsharif Tabebordbar, Jason Cheng et al. · Nature Methods · 2016 · 631 citations · Full text